Maurizio Fava, MD

Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts

JCP
Adjunctive Cariprazine for Anxiety Symptoms in MDD
Original Research

April 30, 2025

Cariprazine added to antidepressant therapy reduced anxiety symptoms in patients with and without anxiety at baseline.
, , , et al
JCP
Long-Term Safety and Efficacy of Esmethadone in MDD
Original Research

February 17, 2025

A durable improvement in MDD symptoms for up to 1 year was observed with esmethadone with high rates of response and remission.
, , , et al
JCP
Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants
Original Research

June 17, 2024

Although this trial of esmethadone did not meet its primary outcome, some secondary and post hoc outcomes were promising.
, , , et al
JCP
Effect of Time From Onset of MDD on Response to Esmethadone
Original Research

May 13, 2024

Esmethadone 25 and 50 mg were more effective in reducing depression scale scores in patients who had a shorter time since their first major depressive episode.
, , , et al
JCP
Heated Yoga for Depression
Original Research

October 23, 2023

Approximately 1 heated yoga session per week for 8 weeks led to significantly greater reduction in depression symptoms than a waitlist control.
, , , et al
JCP
Adjunctive Cariprazine for MDD With Inadequate Response to Antidepressants
Original Research

August 16, 2023

This study assessed the efficacy of adjunctive use of cariprazine, an atypical antipsychotic, in MDD patients with inadequate response to antidepressants.
, , , et al
JCP
In Memoriam: Joseph Biederman, MD
In Memoriam

February 22, 2023

Colleagues and friends remember Joseph Biederman and reflect on his legacy as the father of pediatric psychopharmacology.
, , , et al
PCC
REL-1017 Effects on Cognition in MDD
Original Research

February 14, 2023

REL-1017 improved subjective measures of cognitive impairment, in addition to improving total MADRS and SDQ scores.
, , , et al
JCP
Rapidity of Improvement With Intranasal Esketamine for MDD
Meta-Analysis

December 12, 2022

This meta-analysis found that augmenting antidepressants with intranasal esketamine vs placebo was more effective in reducing depression severity at 24 hours and study endpoint.
, , , et al
JCP
Effect of Benzodiazepines on Antidepressant Effects of Ketamine
Original Research

November 14, 2022

Findings of studies examining the impact of benzodiazepines on antidepressant effects of ketamine are contradictory. This study assessed whether concomitant oral benzodiazepines differentially affected treatment response to ketamine versus...
, , , et al
JCP
Omega-3 Fatty Acids for MDD With High Inflammation
Original Research

August 22, 2022

This study investigated whether dosage or inflammation levels affect response to omega-3s in MDD patients.
, , , et al
JCP
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD
Original Research

May 30, 2022

Altered glutamatergic neurotransmission has been implicated in the pathogenesis of depression. This phase 3 trial evaluated the efficacy and safety of AXS-05 (dextromethorphan-bupropion) in the treatment of major depressive...
, , , et al

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe